# Caspofungin for the Treatment of Non-blood Candida Infections (0991-045)

> **NCT00083343** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 48 (actual)

## Conditions studied

- Candidiasis

## Interventions

- **DRUG:** MK0991, caspofungin acetate/Duration of Treatment: variable

## Key facts

- **NCT ID:** NCT00083343
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** 2006-02
- **Final completion:** 2006-02
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2017-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00083343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00083343, "Caspofungin for the Treatment of Non-blood Candida Infections (0991-045)". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00083343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*